Daratumumab and hyaluronidase-fihj news

• 

  21 January 2026

  Genmab Reports 2025 DARZALEX Sales

  2025 DARZALEX sales reached USD 14,351 million, with USD 8,266 million in the U.S. and USD 6,085 million elsewhere. Genmab earns royalties from J&J's global sales.
• 

  14 January 2026

  Johnson & Johnson's TECVAYLI® Shows Improved Survival in Multiple Myeloma Patients

  TECVAYLI® monotherapy reduces disease progression and death risk in multiple myeloma patients refractory to anti-CD38 and lenalidomide, showing superior survival benefits.
• 

  6 January 2026

  Johnson & Johnson Seeks EMA Approval for TECVAYLI and DARZALEX Combo in Relapsed Multiple Myeloma

  The EMA application is based on Phase 3 data showing improved survival in relapsed multiple myeloma with TECVAYLI and DARZALEX, with similar adverse event rates to standard care.
• 

  15 December 2025

  Janssen's TECVAYLI® and DARZALEX FASPRO® Join FDA's Priority Voucher Program

  TECVAYLI® and DARZALEX FASPRO® show significant survival benefits in multiple myeloma, gaining FDA Breakthrough Therapy Designation and Real-Time Oncology Review.
• 

  9 December 2025

  Johnson & Johnson's Phase 3 Study: TECVAYLI® and DARZALEX FASPRO® Show Promise for Relapsed/Refractory Multiple Myeloma

  TECVAYLI® plus DARZALEX FASPRO® reduces disease progression risk by 83% in RRMM patients, showing improved survival and quality of life over standard care.
• 

  6 November 2025

  Johnson & Johnson's DARZALEX FASPRO®: First FDA-Approved Treatment for High-Risk Smoldering Multiple Myeloma

  DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.